№ files_lp_3_process_7_063455
File format: docx
Character count: 34730
File size: 499 KB
Year:
2020
Region / City:
Naas, Ireland
Topic:
Healthcare, Medical Protocol
Document Type:
Protocol
Organization:
Naas General Hospital
Author:
Joanna Rea
Target Audience:
Gastroenterology team, Clinical Nurse Manager, Nursing staff, IBD Clinical Nurse Specialist
Period of Validity:
January 2023
Approval Date:
14th of January 2020
Date of Revision:
January 2023
Date of Update:
Not specified
Keywords:
Infliximab, infusion, protocol, healthcare, patient safety, staff training, adverse events, gastroenterology
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
Not specified
Region / City:
Not specified
Topic:
Infliximab dose escalation in Crohn’s disease treatment
Document type:
Medical request letter
Institution / Organization:
Not specified
Author:
Not specified
Target audience:
Insurance company
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
Year:
2021
Region / City:
Australia
Topic:
Pharmaceutical Submission
Document Type:
Regulatory Submission
Agency / Institution:
PBAC
Author:
CELLTRION HEALTHCARE AUSTRALIA PTY LTD
Target Audience:
Healthcare professionals, regulatory authorities
Effective Period:
2021 and ongoing
Approval Date:
25 August 2021
Date of Changes:
March 2022
Year:
2022
Region / city:
Australia
Theme:
Rheumatoid Arthritis, Pharmaceutical submission
Document type:
Submission for PBS listing
Organization / institution:
Celltrion Healthcare Australia Pty Ltd
Author:
Celltrion Healthcare Australia Pty Ltd
Target audience:
Health professionals, regulators
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Document Type:
Prior Authorization Request Letter
Subject:
Authorization for intravenous Infliximab treatment
Medication:
Infliximab
Request Type:
Standard or Expedited
Addressee:
Medical Director or Prior Authorization Reviewer
Author:
Healthcare Provider
Related Information:
Diagnosis, ICD Code, Dose and Frequency
Supporting Documentation:
Prescribing Information, Peer-Reviewed Articles, Clinical Guidelines
Purpose:
Coverage and Reimbursement Approval
Clinical Content:
Patient Diagnosis, Treatment History, Prognosis, Rationale for Treatment
Site of Service:
Inpatient or Outpatient Medical Facility
Year:
2015
Region / city:
Australia
Subject:
Pharmaceutical Submissions, Biosimilars
Document Type:
Application for PBS Listing
Organization / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Hospira
Target Audience:
Healthcare professionals, regulatory authorities, pharmaceutical industry
Period of validity:
Ongoing
Approval Date:
N/A
Date of changes:
N/A
Year:
2022
Region / City:
USA
Topic:
Kawasaki Disease Treatment
Document Type:
Research Article
Organization / Institution:
Multiple Medical Centers
Author:
Kaitlyn Krebushevski
Target Audience:
Pediatricians, Researchers
Period of Action:
Ongoing
Approval Date:
January 2022
Modification Date:
Not specified
Methodology:
Literature Review, Meta-Analysis, Randomized Control Trials
Year:
2024
Region / city:
Edinburgh, UK
Topic:
Genetics of Mortality in Critical Care
Document Type:
Study Protocol
Organization / Institution:
University of Edinburgh, NHS Lothian Health Board
Author:
Prof JK Baillie, Ms F Griffiths, Dr S Clohisey, Dr A Law, Dr N Parkinson, Mr L Murphy, Mr Edward Rippingale-Combes
Target Audience:
Researchers, Healthcare professionals
Duration:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / City:
Cincinnati
Subject:
Social and Behavioral Sciences Research
Document Type:
Research Protocol Submission Guidelines
Institution / Organization:
University of Cincinnati
Author:
Not specified
Target Audience:
Researchers submitting to the IRB-S
Validity Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
United States
Theme:
Racial and gender discrimination, military climate, sexual harassment, sexual assault
Document Type:
Research Protocol
Organization / Institution:
Department of Defense, Office of People Analytics (OPA)
Author:
Unknown
Target Audience:
Racial/ethnic minority service members in the U.S. military
Period of Action:
2023
Approval Date:
Unknown
Date of Changes:
Unknown
Version:
1.5.0.0
Protocol Posting Date:
June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2025
Authors:
Gulisa Turashvili, MD, PhD; Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO; Giovanna A. Giannico, MD; Krisztina Hanley, MD; Anna Plotkin, MD; Anthony N. Karnezis, MD, PhD.
Note:
Accreditation Requirements
Date of Protocol Posting:
June 2024
Date of Required Use:
March 2025
Year:
2025
Date:
September 11, 2025
Version:
v1.1
Document type:
Research report
Author:
Edgar Marcelo Quiroz Robles
Affiliation:
Independent Researcher
Field:
Theoretical cosmology and mathematical physics
Framework:
4-Dimensional Elastic Model of the Universe (4DEM)
Related theories:
String theory
Status:
Draft
Repository:
Zenodo
Publication note:
Extended appendices published as Amazon KDP eBooks
Note:
Year
Year:
2026
Version:
NENC v2.0
Date published:
22 January 2026
Planned review date:
October 2027
Region:
North East and North Cumbria
Healthcare system:
NHS
Clinical area:
Neurology
Condition:
Amyotrophic lateral sclerosis
Medicine:
Riluzole
Document type:
Shared care protocol
Indication:
Extension of survival or time to mechanical ventilation in ALS
Target population:
Adults
Intended audience:
NHS healthcare professionals
Initiating authority:
Neurological specialist services
Regulatory reference:
NICE Technology Appraisal TA20
Prescribing setting:
Secondary to primary care transfer
Monitoring requirements:
Liver function tests, full blood count, urea and electrolytes
Route of administration:
Oral or enteral
Licensing status:
Licensed for ALS only
Investigator:
[insert name of principal investigator]
Key Information:
The following is a short summary of this study to help you decide whether or not to be a part of this study. More detailed information is listed later on in this form.
Note:
Why am I being invited to take part in a research study?
You will be asked to _________ [include a high level summary of the procedures that will be done. For example:
You will be given an investigational drug and asked to come for 3 study visits. You will give a total of 3 blood samples and fill out questionnaires asking about how you feel.]
Instead of being in this research study, your choices may include:
[List alternatives procedures. For student subject pools describe alternatives for course credit. For clinical trials describe the options that you would normally offer patient. If applicable, include supportive care as an option.]
Detailed Information:
The following is more detailed information about this study in addition to the information listed above.
[Tell the subject what to expect using lay language and simple terms. Whenever appropriate include the following items:
]
Year:
2020
Type of Document:
Protocol
Organization:
XXXX
Target Audience:
Leadership, Crisis Management Team
Scope:
International
Update Date:
October 2020
Document Sections:
Definitions, Purpose, Crisis Management Team, Escalation Levels, Phases, Strategy, Logs, After-Action Review, Annexures
Note:
Year
Year:
2025
Region / City:
London
Topic:
Neonatal BCG vaccination program
Document Type:
Protocol
Organization / Institution:
NHSE
Author:
Alice Waters
Target Audience:
Healthcare professionals involved in neonatal care and immunization
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
September 2025
Year:
2022
Region / City:
Cheshire and Merseyside
Subject:
Child Protection, Family Law
Document Type:
Practice Note
Issuing Authority:
His Honour Judge Steven Parker, Designated Family Judge for Cheshire and Merseyside
Period of Application:
2022-2023 (pilot phase)
Approval Date:
9th March 2022
Amendment Date:
None
Note:
Date of Application